KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Accumulated Depreciation & Amortization (2016 - 2026)

Pfizer has reported Accumulated Depreciation & Amortization over the past 18 years, most recently at $1.6 billion for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization changed 0.31% to $1.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Mar 2026, changed 0.31% year-over-year, with the annual reading at $6.6 billion for FY2025, 6.0% down from the prior year.
  • Accumulated Depreciation & Amortization was $1.6 billion for Q1 2026 at Pfizer, down from $6.6 billion in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $7.0 billion in Q4 2024 and troughed at $1.5 billion in Q2 2023.
  • The 5-year median for Accumulated Depreciation & Amortization is $3.4 billion (2022), against an average of $3.8 billion.
  • Year-over-year, Accumulated Depreciation & Amortization crashed 43.46% in 2024 and then soared 87.46% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $5.1 billion in 2022, then increased by 24.21% to $6.3 billion in 2023, then rose by 11.49% to $7.0 billion in 2024, then decreased by 6.0% to $6.6 billion in 2025, then tumbled by 75.53% to $1.6 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Accumulated Depreciation & Amortization are $1.6 billion (Q1 2026), $6.6 billion (Q4 2025), and $4.9 billion (Q3 2025).